Sirtex Medical (“Sirtex”), a manufacturer of targeted liver cancer therapy, SIR-Spheres® Y-90 resin microspheres, is pleased to report that positive trial data from the NASIR-HCC Study was reported by Professor Bruno Sangro at the International Liver Cancer Association Virtual Conference (ILCA) on September 13, 2020. NASIR-HCC, a multicenter phase 2 single arm clinical trial, evaluated the safety, tolerability, and preliminary antitumoral efficacy of selective internal radiation therapy (SIRT) using Sirtex's lead product SIR-Spheres® Y-90 resin microspheres, followed by Nivolumab, a targeted anti PD-1 cancer therapy manufactured by Bristol Myers Squibb (BMS), in 42 patients with Hepatocellular Carcinoma (HCC).
The Phase 2 study was conducted across nine academic hospitals in Spain. Patients enrolled in NASIR-HCC had large single or multiple tumors including those with unilobar segmental or lobar portal vein thrombosis, preserved liver function, and no extrahepatic disease. Results showed:
While confirmation with future randomized controlled trials is needed to further explore the efficacy of SIRT treatment followed by Nivolumab, overall response rate (ORR) was observed in 40% of patients, including 12.5% and 27.5% who had a complete tumor and partial tumor response, respectively.
The ILCA presentation was led by the NASIR trial principle investigator, Professor Bruno Sangro, Director of the Liver Unit, and Professor of Internal Medicine at the Clinica Universidad de Navarra in Pamplona, Spain. Professor Sangro received research grants from Sirtex and Bristol Myers Squibb to support the study.
“It's an honor to present our findings to fellow professionals in the liver cancer community so we can advance oncological care for patients demonstrating safety, tolerability and early antitumoral efficacy of combination therapy with SIRT followed by Nivolumab,” said Professor Sangro. “I express deep thanks to our multicenter team, Sirtex, BMS and our other supporters for their efforts to complete this successful study.”
“We’re excited by the study’s positive safety outcomes and look forward to future trials that will further evaluate treatment with SIR-Spheres® Y-90 resin microspheres in combination with effective PD-1 antagonists like Nivolumab possibly providing improved outcomes for patients with oncologic disease by synergistic activation and priming of immune mediated T-Cells,” said Dr. Mark Turco, Chief Medical Officer & EVP R&D Sirtex Medical. “This trial of world class investigators as well as cross industry collaboration demonstrates a great commitment to advance therapies available to patients with cancer.”Back To Top
NASIR-HCC Study of Sirtex SIR-Spheres Shows Safety, Tolerability . Appl Radiol.